SequelSEC

LeonaBio, Inc. LONA

Biological Products, (No Diagnostic Substances) · CIK 0001620463 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$102.27M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

LeonaBio, Inc. (LONA) reported net income of -$105.61M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from LeonaBio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

LeonaBio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$102.27M-$100.90M-$125.47M-$104.02M-$64.02M-$20.00M-$5.45M
Net income-$105.61M-$96.94M-$117.67M-$95.64M-$54.85M-$19.96M-$5.16M
Research & development$17.50M$70.68M$93.79M$61.46M$42.79M$13.29M$3.79M
Weighted-average diluted sharesshares 4.28Mshares 3.85Mshares 38.02Mshares 37.73Mshares 36.92MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable-$19.96M-$5.16M
Income tax expense$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-24.70$-25.19$-3.09$-2.53$-1.49UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$16.68M$26.09M$33.30M$32.55M$21.23M$6.71M$1.66M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

LeonaBio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$69.28M$48.44M$90.58M$95.97M$110.54M$60.62M$2.06M
Total assets$92.15M$58.78M$160.24M$258.15M$332.01M$279.56M$2.19M
Current assets$89.46M$54.84M$154.73M$207.53M$260.80M$192.34M$2.16M
Total liabilities$64.36M$13.94M$30.06M$23.02M$10.92M$5.28M$4.86M
Current liabilities$47.50M$13.14M$28.84M$21.43M$9.29M$4.40M$1.27M
Total equity incl. NCI$27.79M$44.84M$130.19M$235.14M$321.08M$274.28M-$19.72M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$17.05M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.59M$319.00K$129.00K$2.50M$567.00K$1.16M$421.00K

Cash flow

LeonaBio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$45.73M-$97.17M-$100.75M-$72.47M-$43.10M-$24.11M-$3.71M
Capital expendituresUnavailable$33.00K$304.00K$1.14M$1.57M$2.32MUnavailable
Investing cash flow-$15.89M$54.83M$95.09M$57.66M-$4.08M-$210.07M$1.51M
Financing cash flow$82.46M$194.00K$493.00K$654.00K$97.09M$292.75M$946.00K
Net change in cash$20.84M-$42.15M-$5.17M-$14.15M$49.91M$58.57M-$1.26M
Stock-based compensation$6.10M$11.05M$10.62M$10.61M$4.62M$633.00K$253.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

LeonaBio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailable-$97.20M-$101.06M-$73.61M-$44.67M-$26.43MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.88x4.18x5.37x9.68x28.07x43.66x1.70x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LONA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.